Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 3:54 PM
Ignite Modification Date:
2025-12-24 @ 3:54 PM
NCT ID:
NCT00069992
Eligibility Criteria:
INCLUSION CRITERIA:
* Myelodysplastic syndrome with IPSS score \> 0.(Appendix B) Or
* Myeloproliferative disorders
* Primary Myelofibrosis with Lile score of 1 or 2 (Appendix C)
* Polycythemia Vera or Essential Thrombocythemia transformed to AML or Myelofibrosis and PV "spent phase" or
* Acute myelogenous leukemia or
* Chronic myelogenous leukemia
* Available Healthy Donor without any contraindications for donation. 5/6 or 6/6 related donor or 5/6 or 6/6 unrelated donor (molecular typing for DRB1)
* Able to give informed consent
EXCLUSION CRITERIA:
* Patient is pregnant or lactating or unwilling to use contraceptives.
* HIV positive patient
* Uncontrolled intercurrent infection
* Unstable angina and uncompensated congestive heart failure (Zubrod of 3 or greater)
* Severe chronic pulmonary disease requiring oxygen (Zubrod of 3 or greater)
* Hemodialysis dependent.
* Active hepatitis or cirrhosis with total bilirubin, SGOT, and SGPT greater than 3 x normal.
* Concurrent solid organ malignancy not in remission, except for Stage 0 or A prostate cancer.
* Unstable cerebral vascular disease or recent hemorrhagic stroke (less than 6 months)
* Active CNS disease from hematological disorder.
Healthy Volunteers:
False
Sex:
ALL
Study:
NCT00069992
Study Brief:
Protocol Section:
NCT00069992